web analytics
HCQ CHQ Saudi Arabia QPlusNews

 

Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19

Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection (version 2.0) June 17th, 2020

Hydroxychloroquine and Chloroquine
HCQ CHQ Saudi Arabia QPlusNews

Consider starting hydroxychloroquine, if no contraindications:
Adult Dosing: 400 mg every 12 hours for 1 day, followed by 200 mg
BID for 5 – 7 days Pediatric Dosing: 6.5 mg/kg/dose every 12 hours  or day 1 (maximum day 1 dose: 400 mg/dose); followed by 3.25g/kg/dose every 12 hours for 5 – 7 days (maximum dose: 200 mg/dose)”

If hydroxychloroquine is not available, consider chloroquine
Adult Dosing: Chloroquine base 600 mg at diagnosis (equivalent to
chloroquine phosphate 1000 mg), followed by 300 mg (equivalent to
chloroquine phosphate 500 mg) 12 hours later BID for 5 – 7 days Pediatric Dosing: Chloroquine base loading 10 mg/kg orally
(maximum 600 mg) followed by 5 mg/kg orally once daily
(maximum: 300 mg) 6 hours after the loading dose for 5 – 7 days”

Major Drug Interactions

HCQ CHQ Saudi Arabia QPlusNews

Hydroxychloroquine has fewer drug interaction warnings than Chloroquine, but the only one listed on both as being “Highest Risk” is the “QT-prolonging Agents”

HCQ CHQ Saudi Arabia QPlusNews

Now compare the major drug interactions of Hydroxychloroquine and Chloroquine to Lopinavir/Ritonavir. There are five times the amount of major drug interactions and they even have one more “Highest Risk” the HCQ and CHQ: CYP3A4 Substrates & QT-prolonging Agents (Highest Risk). There approximately 500 major drug interactions associated with Lopinavir/Ritonavir.

https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/MOH-therapeutic-protocol-for-COVID-19.pdf

KALETRA (lopinavir and ritonavir) tablet, for oral use
KALETRA (lopinavir and ritonavir) oral solution
Initial U.S. Approval: 2000

HCQ CHQ Saudi Arabia QPlusNews

Lopinavir/Ritonavir (Kaletra) was approved by the FDA in 2000. The prescription label is 64 pages long to cover all the side effects and drug interactions.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021251s052_021906s046lbl.pdf

PLAQUENIL® HYDROXYCHLOROQUINE SULFATE TABLETS, USP

HCQ CHQ Saudi Arabia QPlusNews

By comparison, the FDA prescription label for Hydroxychloroquine only has 11 pages of warnings and drug interactions.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf

ARALEN® CHLOROQUINE PHOSPHATE, USP

HCQ CHQ Saudi Arabia QPlusNews

And Chloroquine only has 10 pages of warnings and drug interactions.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/006002s044lbl.pdf

So why does the FDA approve such a high risk drug with so many potential side effects and major drug interactions? (That question is rhetorical, we know why)

HCQ CHQ Saudi Arabia QPlusNews

HCQ CHQ Saudi Arabia QPlusNews

Because on May 10, 2021 they extended the patent on the drugs until March 26, 2028.

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/091677s000ltr.pdf

HCQ CHQ Saudi Arabia QPlusNews

 

By Paul

PAUL MUADDIB is a journalist, investigator and QAnon with a focus on uncovering the truth.

Leave a Reply

Your email address will not be published. Required fields are marked *